High Throughput Screening Market / HTS Market Size, Share & Trends by Offering (Instruments, Consumables (Reagents, Kits), Software, Services), Technology (Cell-based Assays, Lab-on-Chip, Label-free), Application (Drug Discovery, Life Sciences Research) - Global Forecast to 2029
The global high-throughput screening market size is projected to reach USD 50.2 billion by 2029 from USD 28.8 billion in 2024, at a CAGR of 11.8% during the forecast period. Pharmaceutical & biotechnology companies collaborate with academic institutions, research organizations, and technology providers, enabling them to access external expertise and novel technologies in high-throughput screening (HTS). For instance, in 2023, ChemDiv, Inc. (US) collaborated with the University of Texas Medical Branch (UTMB) to expand its inventory and advance its high throughput screening (HTS) research programs. Furthermore, institutions such as the University of Florida Health (US) collaborate with research groups for various high-throughput screening applications, including assay development, pilot screening, and HTS campaigns. The university’s High Throughput Molecular Screening Center supports researchers by providing grant support for their research Similarly, major pharmaceutical companies, such as Novartis AG (Switzerland), invested USD 3.64 billion in 2023, for exploratory research to discover and develop new drug candidates. This investment was 24% higher than the previous year’s investment. With the increased allocation of resources to research and development by pharmaceutical companies and research institutions, there will be a growing demand for efficient and effective drug discovery technologies like high throughput screening (HTS).
“The services segment is set to register highest growth rate during 2024-2029 in the high throughput screening (HTS) market”
The high-throughput screening (HTS) offerings market is segmented into consumables, instruments, services, and software. Services in the high-throughput screening (HTS) market include high-throughput screening services, assay development services, cell line development services, and microplate development services. These services are essential for high-throughput screening as they offer tools and processes necessary for effective drug discovery and life science research. Factors such as increasing assay complexities for drug development and hit identification, along with the growing demand for cost-effective and specialized high-throughput screening (HTS) expertise drive the growth of the service segment. Service providers also help mitigate research and regulatory risks and allow pharmaceutical and biotechnology companies to focus on their core competencies. Owing to these factors, the high-throughput screening (HTS) services segment has emerged as a beneficial market space for companies and registered the highest growth rate in the market during the forecast period.
“CRO end user segment is set to witness the highest growth rate in the HTS market”
Based on end user, the high-throughput screening market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CROs), and other end users. Contract Research Organizations (CROs) are projected to witness the highest growth rate during the forecast period. This growth can be attributed to factors such as the growing trend of outsourcing of R&D activities by pharmaceutical and biotechnology companies to research organizations such as CROs. High throughput screening (HTS) allows CROs to rapidly screen large libraries of compounds against specific targets, making lead discovery more efficient. By identifying unsuitable compounds early, CROs can reduce costs and risks for their pharmaceutical clients, saving time and money and minimizing the risk of late-stage failures. CROs are investing in advanced HTS technologies and infrastructure, allowing them to perform complex screens not feasible for smaller companies. For instance, Labcorp Drug Development services use robotic screening systems, and Parexel integrates AI and machine learning with HTS to enhance their screening capabilities
“Drug Discovery segment accounted for the highest CAGR”
Based on application, the high-throughput screening (HTS) market is segmented into drug discovery, biochemical screening, life sciences research, and other applications. The drug discovery segment is projected to grow with the highest CAGR throughout 2024 to 2029. The key factor driving this segment's growth is the increasing prevalence of diseases leading to a rise in pharmaceutical drug discovery research and development. Pharmaceutical companies are utilizing this technology for lead discovery, target validation, primary screening, compound profiling, and hit identification Additionally, ongoing advancements such as automation and AI integration, in high-throughput screening (HTS) technologies further aid in making the drug discovery process more efficient and cost-effective supporting the growth of the market.
“Asia Pacific: The fastest-growing country in the high-throughput screening market”
The high-throughput screening (HTS) market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Factors such as rising pharmaceutical R&D spending, growing public-private partnerships, and increasing government funding drive the growth of the HTS market in this region.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the high throughput screening market. It aims at estimating the size and future growth potential of the market across different segments, such as offerings, technology, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Reasons to Buy the Report:
The report provides insights on the following pointers:
“The services segment is set to register highest growth rate during 2024-2029 in the high throughput screening (HTS) market”
The high-throughput screening (HTS) offerings market is segmented into consumables, instruments, services, and software. Services in the high-throughput screening (HTS) market include high-throughput screening services, assay development services, cell line development services, and microplate development services. These services are essential for high-throughput screening as they offer tools and processes necessary for effective drug discovery and life science research. Factors such as increasing assay complexities for drug development and hit identification, along with the growing demand for cost-effective and specialized high-throughput screening (HTS) expertise drive the growth of the service segment. Service providers also help mitigate research and regulatory risks and allow pharmaceutical and biotechnology companies to focus on their core competencies. Owing to these factors, the high-throughput screening (HTS) services segment has emerged as a beneficial market space for companies and registered the highest growth rate in the market during the forecast period.
“CRO end user segment is set to witness the highest growth rate in the HTS market”
Based on end user, the high-throughput screening market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CROs), and other end users. Contract Research Organizations (CROs) are projected to witness the highest growth rate during the forecast period. This growth can be attributed to factors such as the growing trend of outsourcing of R&D activities by pharmaceutical and biotechnology companies to research organizations such as CROs. High throughput screening (HTS) allows CROs to rapidly screen large libraries of compounds against specific targets, making lead discovery more efficient. By identifying unsuitable compounds early, CROs can reduce costs and risks for their pharmaceutical clients, saving time and money and minimizing the risk of late-stage failures. CROs are investing in advanced HTS technologies and infrastructure, allowing them to perform complex screens not feasible for smaller companies. For instance, Labcorp Drug Development services use robotic screening systems, and Parexel integrates AI and machine learning with HTS to enhance their screening capabilities
“Drug Discovery segment accounted for the highest CAGR”
Based on application, the high-throughput screening (HTS) market is segmented into drug discovery, biochemical screening, life sciences research, and other applications. The drug discovery segment is projected to grow with the highest CAGR throughout 2024 to 2029. The key factor driving this segment's growth is the increasing prevalence of diseases leading to a rise in pharmaceutical drug discovery research and development. Pharmaceutical companies are utilizing this technology for lead discovery, target validation, primary screening, compound profiling, and hit identification Additionally, ongoing advancements such as automation and AI integration, in high-throughput screening (HTS) technologies further aid in making the drug discovery process more efficient and cost-effective supporting the growth of the market.
“Asia Pacific: The fastest-growing country in the high-throughput screening market”
The high-throughput screening (HTS) market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Factors such as rising pharmaceutical R&D spending, growing public-private partnerships, and increasing government funding drive the growth of the HTS market in this region.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side -80% and Demand Side – 20%
- By Designation: Managers -45%, CXOs and Directors -30%, and Executives – 25%
- By Region: North America-55%, Europe -15%, Asia-Pacific -15%, Latin America-10%, Middle East and Africa-5%
- Thermo Fisher Scientific Inc. (US)
- Agilent Technologies, Inc. (US)
- Merck KGaA (Germany)
- Danaher Corporation (US)
- Revvity, Inc. (US)
- Tecan Group Ltd. (Switzerland)
- Bio-Rad Laboratories, Inc. (US)
- Corning Incorporated (US)
- Mettler-Toledo International Inc. (US)
- Lonza Group (Switzerland)
- Waters Corporation (US)
- Sartorius AG (Germany)
- Eppendorf SE (Germany)
- Porvair Plc (UK)
- Greiner AG (Austria)
- Charles River Laboratories (US)
- Eurofins Scientific (Luxembourg)
- Hamilton Company (US)
- Aurora Biomed Inc. (Canada)
- Gilson Incorporated (US)
- Brand GmbH+Co KG (Germany)
- BMG Labtech GmbH (Germany)
- DIANA Biotechnologies (Czechia)
- A.S. (Czech Republic)
- Creative Biolabs (US)
- HighRes Biosolutions (US)
- Biomat Srl, (Italy)
- Axxam S.p.A. (Italy)
- Sygnature Discovery Limited (UK)
- Crown Bioscience (US)
This report provides a detailed picture of the high throughput screening market. It aims at estimating the size and future growth potential of the market across different segments, such as offerings, technology, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Reasons to Buy the Report:
The report provides insights on the following pointers:
- Analysis of key drivers (the growing adoption of open innovative models in pharmaceutical & biotechnology companies, rising government funding and venture capital investments, increasing R&D spending, and technological advancements), restraints (high costs of using HTS instruments), opportunities (increasing adoption of HTS technologies in emerging markets, growing research on novel therapeutics and application of HTS technology in drug repurposing), and challenges (lack of skilled operators, and complexities in data management, assay development, and analysis) influencing the growth of the high throughput screening (HTS) market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the high throughput screening (HTS) market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various high-throughput screening opportunities and developments across key geographic regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the high-throughput screening (HTS) market.
- Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players like Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Revvity, Inc. (US), among others in the high-throughput screening market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 INSIGHTS FROM PRIMARIES
2.3 MARKET GROWTH FORECAST
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ON HIGH-THROUGHPUT SCREENING (HTS) MARKET
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 HIGH-THROUGHPUT SCREENING (HTS) MARKET OVERVIEW
4.2 NORTH AMERICA: HIGH-THROUGHPUT SCREENING (HTS) MARKET SHARE, BY OFFERING AND COUNTRY (2023)
4.3 HIGH-THROUGHPUT SCREENING (HTS) MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
4.4 HIGH-THROUGHPUT SCREENING (HTS) MARKET SHARE, BY END USER, 2023
4.5 HIGH-THROUGHPUT SCREENING (HTS) MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing adoption of open innovation models
5.2.1.2 Rising government funding and venture capital investments
5.2.1.3 Increasing R&D spending
5.2.1.4 Technological advancements
5.2.2 RESTRAINTS
5.2.2.1 High cost of using HTS instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing adoption of HTS technologies in emerging markets
5.2.3.2 Growing research on novel therapeutics
5.2.3.3 Drug repurposing
5.2.4 CHALLENGES
5.2.4.1 Lack of skilled operators
5.2.4.2 Complexities in data management, assay development, and analysis
5.3 INDUSTRY TRENDS
5.3.1 ADOPTION OF PHENOTYPIC SCREENING
5.3.2 AUTOMATION AND AI INTEGRATION
5.3.3 RISE OF CRISPR TECHNOLOGY
5.3.4 INTEGRATION OF SINGLE-CELL ANALYSIS TECHNOLOGIES
5.3.5 REGULATORY CONSIDERATIONS
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 High-content screening/analysis
5.4.1.2 Label-free detection (surface plasmon resonance)
5.4.2 COMPLEMENTARY TECHNOLOGIES
5.4.2.1 Microfluidics, organ-on-a-chip (OOC), and lab-on-a-chip (LOC)
5.4.2.2 Mass spectrometry (MS)
5.4.2.3 Flow cytometry
5.4.3 ADJACENT TECHNOLOGIES
5.4.3.1 Fragment-based drug discovery
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.6 PRICING ANALYSIS
5.7 VALUE CHAIN ANALYSIS
5.8 SUPPLY CHAIN ANALYSIS
5.9 ECOSYSTEM ANALYSIS
5.9.1 HIGH-THROUGHPUT SCREENING MARKET: ROLE OF RAW MATERIAL VENDORS
5.9.2 HIGH-THROUGHPUT SCREENING MARKET: ROLE OF PRODUCT & SERVICE PROVIDERS
5.9.3 HIGH-THROUGHPUT SCREENING MARKET: ROLE OF END USERS
5.9.4 HIGH-THROUGHPUT SCREENING MARKET: ROLE OF REGULATORY AUTHORITIES
5.1 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA FOR SPECTROMETERS
5.11.2 IMPORT DATA FOR MASS SPECTROMETERS
5.11.3 EXPORT DATA FOR SPECTROMETERS
5.11.4 EXPORT DATA FOR MASS SPECTROMETERS
5.12 REGULATORY ANALYSIS
5.12.1 REGULATORY LANDSCAPE
5.12.1.1 US
5.12.1.2 Europe
5.12.1.3 Emerging markets
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 INTENSITY OF COMPETITIVE RIVALRY
5.13.2 BARGAINING POWER OF SUPPLIERS
5.13.3 BARGAINING POWER OF BUYERS
5.13.4 THREAT OF SUBSTITUTES
5.13.5 THREAT OF NEW ENTRANTS
5.14 KEY CONFERENCES & EVENTS, 2024–2025
5.15 KEY STAKEHOLDERS & BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS OF HIGH-THROUGHPUT SCREENING PRODUCTS & SERVICES: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
5.15.2 BUYING CRITERIA FOR HIGH-THROUGHPUT SCREENING PRODUCTS & SERVICES
5.15.3 BUYING CRITERIA FOR HIGH-THROUGHPUT SCREENING PRODUCTS & SERVICES, BY END USER
6 HIGH-THROUGHPUT SCREENING (HTS) MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 REAGENTS & ASSAY KITS
6.2.1.1 Growing applications of HTS in drug discovery and life science research to support demand for consumables
6.2.2 LABORATORY CONSUMABLES
6.2.2.1 Growing automation in high-throughput screening to propel market growth
6.3 INSTRUMENTS
6.3.1 LIQUID HANDLING SYSTEMS
6.3.1.1 Ongoing technological advancements and automation to support market growth
6.3.2 DETECTION SYSTEMS
6.3.2.1 High demand for high-throughput and sensitive detection systems to propel market
6.3.3 IMAGING INSTRUMENTS
6.3.3.1 Advancements in high-content imaging systems to boost market
6.3.4 OTHER INSTRUMENTS
6.4 SERVICES
6.4.1 INCREASING ASSAY COMPLEXITIES AND GROWING NEED FOR COST-EFFECTIVE AND SPECIALIZED HTS EXPERTISE TO BOOST DEMAND
6.5 SOFTWARE
6.5.1 ONGOING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING SOFTWARE TOOLS TO DRIVE MARKET
7 HIGH-THROUGHPUT SCREENING (HTS) MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 DRUG DISCOVERY
7.2.1 GROWING DEMAND FOR MORE EFFECTIVE METHODS TO IDENTIFY NEW DRUG CANDIDATES TO SUPPORT MARKET GROWTH
7.3 BIOCHEMICAL SCREENING
7.3.1 GROWING AWARENESS OF GENETIC DISORDERS AND SCREENING TESTS TO BOOST MARKET GROWTH
7.4 LIFE SCIENCE RESEARCH
7.4.1 INCREASING INVESTMENTS IN STEM CELL RESEARCH TO CONTRIBUTE TO MARKET GROWTH
7.5 OTHER APPLICATIONS
8 HIGH-THROUGHPUT SCREENING MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
8.2 CELL-BASED ASSAYS
8.2.1 2D CELL CULTURES
8.2.1.1 Cost-effectiveness of 2D cell cultures to promote market growth
8.2.2 3D CELL CULTURES
8.2.2.1 Scaffold-based technology
8.2.2.1.1 Hydrogels
8.2.2.1.1.1 Animal-derived hydrogels
8.2.2.1.1.1.1 Matrigel
8.2.2.1.1.1.1.1 Increasing applications of Matrigel in drug discovery and life science research to support market growth
8.2.2.1.1.1.2 Collagen
8.2.2.1.1.1.2.1 Growing demand for personalized medicines to support market growth
8.2.2.1.1.2 Synthetic hydrogels
8.2.2.1.1.2.1 Better consistency and low risk of contamination to increase adoption and drive growth
8.2.2.1.1.3 Alginate/Agarose
8.2.2.1.1.3.1 Ability of alginate to enhance accuracy and relevance to propel adoption
8.2.2.1.2 Inert matrices/Solid scaffolds
8.2.2.1.2.1 Lack of native-like microenvironment and other disadvantages to restrain growth
8.2.2.1.3 Micropatterned surfaces
8.2.2.1.3.1 Greater enzyme levels and drug reactivity to support adoption
8.2.2.2 Scaffold-free technology
8.2.2.2.1 Ultra-low-binding plates
8.2.2.2.1.1 Demand for high-quality, low-background assays to boost market
8.2.2.2.2 Hanging-drop plates
8.2.2.2.2.1 Cost-effectiveness to boost adoption among end users
8.2.2.2.3 Other scaffold-free technologies
8.2.3 REPORTER-BASED ASSAYS
8.2.3.1 Growing applications of gene expression to support growth
8.2.4 PERFUSION CELL CULTURES
8.2.4.1 Ongoing research to develop perfusion cell culture technology for drug discovery to support adoption
8.3 LAB-ON-A-CHIP
8.3.1 INCREASING APPLICATIONS OF LAB-ON-A-CHIP TECHNOLOGY FOR HTS AND PRECISION MEDICINE DEVELOPMENT TO SUPPORT MARKET GROWTH
8.4 LABEL-FREE TECHNOLOGY
8.4.1 ABILITY TO CONDUCT LABEL-FREE INVESTIGATION OF BIOMOLECULAR INTERACTIONS TO PROPEL ADOPTION
9 HIGH-THROUGHPUT SCREENING (HTS) MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 GROWING DEMAND FOR HTS SOLUTIONS IN LEAD DISCOVERY TO SUPPORT MARKET GROWTH
9.3 ACADEMIC & RESEARCH INSTITUTES
9.3.1 GROWING ADOPTION OF HTS IN COLLABORATIVE ACADEMIC & RESEARCH ACTIVITIES TO AID MARKET GROWTH
9.4 CONTRACT RESEARCH ORGANIZATIONS (CROS)
9.4.1 INCREASING OUTSOURCING OF R&D ACTIVITIES TO DRIVE MARKET GROWTH FOR CROS
9.5 OTHER END USERS
10 HIGH-THROUGHPUT SCREENING (HTS) MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 Presence of major research institutes and key pharmaceutical companies to support market growth
10.2.3 CANADA
10.2.3.1 Government initiatives promoting research to support market growth
10.3 EUROPE
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Increasing research initiatives to boost market growth
10.3.3 UK
10.3.3.1 Investments by pharmaceutical sponsors for drug discovery to support market
10.3.4 FRANCE
10.3.4.1 Large pharmaceutical R&D expenditure to drive market growth
10.3.5 ITALY
10.3.5.1 Strong collaborative research networks to fuel growth
10.3.6 SPAIN
10.3.6.1 Rising R&D expenditure and increasing public-private partnerships to boost market
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 CHINA
10.4.2.1 Growing research and collaborations in field of drug discovery to support growth of market
10.4.3 JAPAN
10.4.3.1 Growing focus on research and strategic collaborations to support market growth
10.4.4 INDIA
10.4.4.1 Developing healthcare industry and ongoing government initiatives to create favorable opportunities for market players
10.4.5 AUSTRALIA
10.4.5.1 Growing pharmaceutical industry to create favorable opportunities for market players
10.4.6 SOUTH KOREA
10.4.6.1 Growing pharmaceutical industry to favor market growth
10.4.7 REST OF ASIA PACIFIC (ROAPAC)
10.5 LATIN AMERICA
10.5.1 LATIN AMERICA: RECESSION IMPACT
10.5.2 BRAZIL
10.5.2.1 Gradual growth in research to contribute to growth
10.5.3 MEXICO
10.5.3.1 Favorable government support to contribute to growth
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST
10.6.1 MIDDLE EAST: RECESSION IMPACT
10.6.2 GCC COUNTRIES
10.6.2.1 Saudi Arabia
10.6.2.1.1 Growing pharmaceuticals industry to support market growth
10.6.2.2 UAE
10.6.2.2.1 High R&D expenditure and advanced healthcare infrastructure to boost market growth
10.6.2.3 Rest of GCC Countries
10.7 AFRICA
10.7.1 INCREASING FUNDING AND PARTNERSHIPS IN RESEARCH SECTOR TO AID MARKET GROWTH
10.7.2 AFRICA: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HIGH-THROUGHPUT SCREENING (HTS) MARKET
11.3 REVENUE ANALYSIS
11.4 MARKET SHARE ANALYSIS
11.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
11.5.5.2 Offering footprint
11.5.5.3 Application footprint
11.5.5.4 Region footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.7 COMPANY VALUATION & FINANCIAL METRICS
11.7.1 FINANCIAL METRICS
11.7.2 COMPANY VALUATION
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES
11.9.2 DEALS
11.9.3 EXPANSIONS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 THERMO FISHER SCIENTIFIC INC.
12.1.1.1 Business overview
12.1.1.2 Products & services offered
12.1.1.3 Recent developments
12.1.1.3.1 Product launches & approvals
12.1.1.3.2 Deals
12.1.1.3.3 Expansions
12.1.1.4 MnM view
12.1.1.4.1 Right to win
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses & competitive threats
12.1.2 AGILENT TECHNOLOGIES, INC.
12.1.2.1 Business overview
12.1.2.2 Products & services offered
12.1.2.3 Recent developments
12.1.2.3.1 Product launches & upgrades
12.1.2.3.2 Deals
12.1.2.4 MnM view
12.1.2.4.1 Right to win
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 MERCK KGAA
12.1.3.1 Business overview
12.1.3.2 Products & services offered
12.1.3.3 Recent developments
12.1.3.3.1 Other developments
12.1.3.4 MnM view
12.1.3.4.1 Right to win
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses & competitive threats
12.1.4 DANAHER CORPORATION
12.1.4.1 Business overview
12.1.4.2 Products & services offered
12.1.4.3 Recent developments
12.1.4.3.1 Product & service launches
12.1.4.3.2 Deals
12.1.4.3.3 Expansions
12.1.5 REVVITY, INC.
12.1.5.1 Business overview
12.1.5.2 Products & services offered
12.1.5.3 Recent developments
12.1.5.3.1 Product launches
12.1.5.3.2 Deals
12.1.6 TECAN GROUP LTD.
12.1.6.1 Business overview
12.1.6.2 Products & service offered
12.1.6.3 Recent developments
12.1.6.3.1 Product launches & upgrades
12.1.6.3.2 Deals
12.1.7 BIO-RAD LABORATORIES, INC.
12.1.7.1 Business overview
12.1.7.2 Products & services offered
12.1.7.3 Recent developments
12.1.7.3.1 Product launches
12.1.8 CORNING INCORPORATED
12.1.8.1 Business overview
12.1.8.2 Products & services offered
12.1.8.3 Recent developments
12.1.8.3.1 Product launches
12.1.9 METTLER-TOLEDO INTERNATIONAL INC.
12.1.9.1 Business overview
12.1.9.2 Products & services offered
12.1.9.3 Recent developments
12.1.9.3.1 Product launches
12.1.10 LONZA GROUP
12.1.10.1 Business overview
12.1.10.2 Products & services offered
12.1.10.3 Recent developments
12.1.10.3.1 Deals
12.1.11 WATERS CORPORATION
12.1.11.1 Business overview
12.1.11.2 Products & services offered
12.1.11.3 Recent developments
12.1.11.3.1 Product launches
12.1.11.3.2 Deals
12.1.12 SARTORIUS AG
12.1.12.1 Business overview
12.1.12.2 Products & services offered
12.1.12.3 Recent developments
12.1.12.3.1 Product launches
12.1.13 EPPENDORF SE
12.1.13.1 Business overview
12.1.13.2 Products & services offered
12.1.13.3 Recent developments
12.1.13.3.1 Deals
12.1.13.3.2 Expansions
12.1.14 PORVAIR PLC
12.1.14.1 Business overview
12.1.14.2 Products & services offered
12.1.15 GREINER AG
12.1.15.1 Business overview
12.1.15.2 Products & services offered
12.1.16 CHARLES RIVER LABORATORIES
12.1.16.1 Business overview
12.1.16.2 products & services offered
12.1.16.3 Recent developments
12.1.16.3.1 Deals
12.1.17 EUROFINS SCIENTIFIC
12.1.17.1 Business overview
12.1.17.2 Products & services offered
12.1.17.3 Recent developments
12.1.17.3.1 Service launches
12.1.17.3.2 Deals
12.1.17.3.3 Expansions
12.1.18 HAMILTON COMPANY
12.1.18.1 Business overview
12.1.18.2 Products & services offered
12.1.18.3 Recent developments
12.1.18.3.1 Product launches
12.1.18.3.2 Deals
12.1.19 AURORA BIOMED INC.
12.1.19.1 Business overview
12.1.19.2 Products & services offered
12.1.20 GILSON INCORPORATED
12.1.20.1 Business overview
12.1.20.2 Products & services offered
12.1.20.3 Recent developments
12.1.20.3.1 Product launches
12.1.20.3.2 Deals
12.1.21 BRAND GMBH + CO KG
12.1.21.1 Business overview
12.1.21.2 Products & services offered
12.1.21.3 Recent developments
12.1.21.3.1 Expansions
12.2 OTHER PLAYERS
12.2.1 BMG LABTECH GMBH
12.2.2 DIANA BIOTECHNOLOGIES, A.S.
12.2.3 CREATIVE BIOLABS
12.2.4 HIGHRES BIOSOLUTIONS
12.2.5 BIOMAT SRL
12.2.6 AXXAM S.P.A.
12.2.7 SYGNATURE DISCOVERY LIMITED
12.2.8 CROWN BIOSCIENCE
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 INSIGHTS FROM PRIMARIES
2.3 MARKET GROWTH FORECAST
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ON HIGH-THROUGHPUT SCREENING (HTS) MARKET
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 HIGH-THROUGHPUT SCREENING (HTS) MARKET OVERVIEW
4.2 NORTH AMERICA: HIGH-THROUGHPUT SCREENING (HTS) MARKET SHARE, BY OFFERING AND COUNTRY (2023)
4.3 HIGH-THROUGHPUT SCREENING (HTS) MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
4.4 HIGH-THROUGHPUT SCREENING (HTS) MARKET SHARE, BY END USER, 2023
4.5 HIGH-THROUGHPUT SCREENING (HTS) MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing adoption of open innovation models
5.2.1.2 Rising government funding and venture capital investments
5.2.1.3 Increasing R&D spending
5.2.1.4 Technological advancements
5.2.2 RESTRAINTS
5.2.2.1 High cost of using HTS instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing adoption of HTS technologies in emerging markets
5.2.3.2 Growing research on novel therapeutics
5.2.3.3 Drug repurposing
5.2.4 CHALLENGES
5.2.4.1 Lack of skilled operators
5.2.4.2 Complexities in data management, assay development, and analysis
5.3 INDUSTRY TRENDS
5.3.1 ADOPTION OF PHENOTYPIC SCREENING
5.3.2 AUTOMATION AND AI INTEGRATION
5.3.3 RISE OF CRISPR TECHNOLOGY
5.3.4 INTEGRATION OF SINGLE-CELL ANALYSIS TECHNOLOGIES
5.3.5 REGULATORY CONSIDERATIONS
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 High-content screening/analysis
5.4.1.2 Label-free detection (surface plasmon resonance)
5.4.2 COMPLEMENTARY TECHNOLOGIES
5.4.2.1 Microfluidics, organ-on-a-chip (OOC), and lab-on-a-chip (LOC)
5.4.2.2 Mass spectrometry (MS)
5.4.2.3 Flow cytometry
5.4.3 ADJACENT TECHNOLOGIES
5.4.3.1 Fragment-based drug discovery
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.6 PRICING ANALYSIS
5.7 VALUE CHAIN ANALYSIS
5.8 SUPPLY CHAIN ANALYSIS
5.9 ECOSYSTEM ANALYSIS
5.9.1 HIGH-THROUGHPUT SCREENING MARKET: ROLE OF RAW MATERIAL VENDORS
5.9.2 HIGH-THROUGHPUT SCREENING MARKET: ROLE OF PRODUCT & SERVICE PROVIDERS
5.9.3 HIGH-THROUGHPUT SCREENING MARKET: ROLE OF END USERS
5.9.4 HIGH-THROUGHPUT SCREENING MARKET: ROLE OF REGULATORY AUTHORITIES
5.1 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA FOR SPECTROMETERS
5.11.2 IMPORT DATA FOR MASS SPECTROMETERS
5.11.3 EXPORT DATA FOR SPECTROMETERS
5.11.4 EXPORT DATA FOR MASS SPECTROMETERS
5.12 REGULATORY ANALYSIS
5.12.1 REGULATORY LANDSCAPE
5.12.1.1 US
5.12.1.2 Europe
5.12.1.3 Emerging markets
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 INTENSITY OF COMPETITIVE RIVALRY
5.13.2 BARGAINING POWER OF SUPPLIERS
5.13.3 BARGAINING POWER OF BUYERS
5.13.4 THREAT OF SUBSTITUTES
5.13.5 THREAT OF NEW ENTRANTS
5.14 KEY CONFERENCES & EVENTS, 2024–2025
5.15 KEY STAKEHOLDERS & BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS OF HIGH-THROUGHPUT SCREENING PRODUCTS & SERVICES: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
5.15.2 BUYING CRITERIA FOR HIGH-THROUGHPUT SCREENING PRODUCTS & SERVICES
5.15.3 BUYING CRITERIA FOR HIGH-THROUGHPUT SCREENING PRODUCTS & SERVICES, BY END USER
6 HIGH-THROUGHPUT SCREENING (HTS) MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 REAGENTS & ASSAY KITS
6.2.1.1 Growing applications of HTS in drug discovery and life science research to support demand for consumables
6.2.2 LABORATORY CONSUMABLES
6.2.2.1 Growing automation in high-throughput screening to propel market growth
6.3 INSTRUMENTS
6.3.1 LIQUID HANDLING SYSTEMS
6.3.1.1 Ongoing technological advancements and automation to support market growth
6.3.2 DETECTION SYSTEMS
6.3.2.1 High demand for high-throughput and sensitive detection systems to propel market
6.3.3 IMAGING INSTRUMENTS
6.3.3.1 Advancements in high-content imaging systems to boost market
6.3.4 OTHER INSTRUMENTS
6.4 SERVICES
6.4.1 INCREASING ASSAY COMPLEXITIES AND GROWING NEED FOR COST-EFFECTIVE AND SPECIALIZED HTS EXPERTISE TO BOOST DEMAND
6.5 SOFTWARE
6.5.1 ONGOING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING SOFTWARE TOOLS TO DRIVE MARKET
7 HIGH-THROUGHPUT SCREENING (HTS) MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 DRUG DISCOVERY
7.2.1 GROWING DEMAND FOR MORE EFFECTIVE METHODS TO IDENTIFY NEW DRUG CANDIDATES TO SUPPORT MARKET GROWTH
7.3 BIOCHEMICAL SCREENING
7.3.1 GROWING AWARENESS OF GENETIC DISORDERS AND SCREENING TESTS TO BOOST MARKET GROWTH
7.4 LIFE SCIENCE RESEARCH
7.4.1 INCREASING INVESTMENTS IN STEM CELL RESEARCH TO CONTRIBUTE TO MARKET GROWTH
7.5 OTHER APPLICATIONS
8 HIGH-THROUGHPUT SCREENING MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
8.2 CELL-BASED ASSAYS
8.2.1 2D CELL CULTURES
8.2.1.1 Cost-effectiveness of 2D cell cultures to promote market growth
8.2.2 3D CELL CULTURES
8.2.2.1 Scaffold-based technology
8.2.2.1.1 Hydrogels
8.2.2.1.1.1 Animal-derived hydrogels
8.2.2.1.1.1.1 Matrigel
8.2.2.1.1.1.1.1 Increasing applications of Matrigel in drug discovery and life science research to support market growth
8.2.2.1.1.1.2 Collagen
8.2.2.1.1.1.2.1 Growing demand for personalized medicines to support market growth
8.2.2.1.1.2 Synthetic hydrogels
8.2.2.1.1.2.1 Better consistency and low risk of contamination to increase adoption and drive growth
8.2.2.1.1.3 Alginate/Agarose
8.2.2.1.1.3.1 Ability of alginate to enhance accuracy and relevance to propel adoption
8.2.2.1.2 Inert matrices/Solid scaffolds
8.2.2.1.2.1 Lack of native-like microenvironment and other disadvantages to restrain growth
8.2.2.1.3 Micropatterned surfaces
8.2.2.1.3.1 Greater enzyme levels and drug reactivity to support adoption
8.2.2.2 Scaffold-free technology
8.2.2.2.1 Ultra-low-binding plates
8.2.2.2.1.1 Demand for high-quality, low-background assays to boost market
8.2.2.2.2 Hanging-drop plates
8.2.2.2.2.1 Cost-effectiveness to boost adoption among end users
8.2.2.2.3 Other scaffold-free technologies
8.2.3 REPORTER-BASED ASSAYS
8.2.3.1 Growing applications of gene expression to support growth
8.2.4 PERFUSION CELL CULTURES
8.2.4.1 Ongoing research to develop perfusion cell culture technology for drug discovery to support adoption
8.3 LAB-ON-A-CHIP
8.3.1 INCREASING APPLICATIONS OF LAB-ON-A-CHIP TECHNOLOGY FOR HTS AND PRECISION MEDICINE DEVELOPMENT TO SUPPORT MARKET GROWTH
8.4 LABEL-FREE TECHNOLOGY
8.4.1 ABILITY TO CONDUCT LABEL-FREE INVESTIGATION OF BIOMOLECULAR INTERACTIONS TO PROPEL ADOPTION
9 HIGH-THROUGHPUT SCREENING (HTS) MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 GROWING DEMAND FOR HTS SOLUTIONS IN LEAD DISCOVERY TO SUPPORT MARKET GROWTH
9.3 ACADEMIC & RESEARCH INSTITUTES
9.3.1 GROWING ADOPTION OF HTS IN COLLABORATIVE ACADEMIC & RESEARCH ACTIVITIES TO AID MARKET GROWTH
9.4 CONTRACT RESEARCH ORGANIZATIONS (CROS)
9.4.1 INCREASING OUTSOURCING OF R&D ACTIVITIES TO DRIVE MARKET GROWTH FOR CROS
9.5 OTHER END USERS
10 HIGH-THROUGHPUT SCREENING (HTS) MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 Presence of major research institutes and key pharmaceutical companies to support market growth
10.2.3 CANADA
10.2.3.1 Government initiatives promoting research to support market growth
10.3 EUROPE
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Increasing research initiatives to boost market growth
10.3.3 UK
10.3.3.1 Investments by pharmaceutical sponsors for drug discovery to support market
10.3.4 FRANCE
10.3.4.1 Large pharmaceutical R&D expenditure to drive market growth
10.3.5 ITALY
10.3.5.1 Strong collaborative research networks to fuel growth
10.3.6 SPAIN
10.3.6.1 Rising R&D expenditure and increasing public-private partnerships to boost market
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 CHINA
10.4.2.1 Growing research and collaborations in field of drug discovery to support growth of market
10.4.3 JAPAN
10.4.3.1 Growing focus on research and strategic collaborations to support market growth
10.4.4 INDIA
10.4.4.1 Developing healthcare industry and ongoing government initiatives to create favorable opportunities for market players
10.4.5 AUSTRALIA
10.4.5.1 Growing pharmaceutical industry to create favorable opportunities for market players
10.4.6 SOUTH KOREA
10.4.6.1 Growing pharmaceutical industry to favor market growth
10.4.7 REST OF ASIA PACIFIC (ROAPAC)
10.5 LATIN AMERICA
10.5.1 LATIN AMERICA: RECESSION IMPACT
10.5.2 BRAZIL
10.5.2.1 Gradual growth in research to contribute to growth
10.5.3 MEXICO
10.5.3.1 Favorable government support to contribute to growth
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST
10.6.1 MIDDLE EAST: RECESSION IMPACT
10.6.2 GCC COUNTRIES
10.6.2.1 Saudi Arabia
10.6.2.1.1 Growing pharmaceuticals industry to support market growth
10.6.2.2 UAE
10.6.2.2.1 High R&D expenditure and advanced healthcare infrastructure to boost market growth
10.6.2.3 Rest of GCC Countries
10.7 AFRICA
10.7.1 INCREASING FUNDING AND PARTNERSHIPS IN RESEARCH SECTOR TO AID MARKET GROWTH
10.7.2 AFRICA: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HIGH-THROUGHPUT SCREENING (HTS) MARKET
11.3 REVENUE ANALYSIS
11.4 MARKET SHARE ANALYSIS
11.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
11.5.5.2 Offering footprint
11.5.5.3 Application footprint
11.5.5.4 Region footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.7 COMPANY VALUATION & FINANCIAL METRICS
11.7.1 FINANCIAL METRICS
11.7.2 COMPANY VALUATION
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES
11.9.2 DEALS
11.9.3 EXPANSIONS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 THERMO FISHER SCIENTIFIC INC.
12.1.1.1 Business overview
12.1.1.2 Products & services offered
12.1.1.3 Recent developments
12.1.1.3.1 Product launches & approvals
12.1.1.3.2 Deals
12.1.1.3.3 Expansions
12.1.1.4 MnM view
12.1.1.4.1 Right to win
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses & competitive threats
12.1.2 AGILENT TECHNOLOGIES, INC.
12.1.2.1 Business overview
12.1.2.2 Products & services offered
12.1.2.3 Recent developments
12.1.2.3.1 Product launches & upgrades
12.1.2.3.2 Deals
12.1.2.4 MnM view
12.1.2.4.1 Right to win
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 MERCK KGAA
12.1.3.1 Business overview
12.1.3.2 Products & services offered
12.1.3.3 Recent developments
12.1.3.3.1 Other developments
12.1.3.4 MnM view
12.1.3.4.1 Right to win
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses & competitive threats
12.1.4 DANAHER CORPORATION
12.1.4.1 Business overview
12.1.4.2 Products & services offered
12.1.4.3 Recent developments
12.1.4.3.1 Product & service launches
12.1.4.3.2 Deals
12.1.4.3.3 Expansions
12.1.5 REVVITY, INC.
12.1.5.1 Business overview
12.1.5.2 Products & services offered
12.1.5.3 Recent developments
12.1.5.3.1 Product launches
12.1.5.3.2 Deals
12.1.6 TECAN GROUP LTD.
12.1.6.1 Business overview
12.1.6.2 Products & service offered
12.1.6.3 Recent developments
12.1.6.3.1 Product launches & upgrades
12.1.6.3.2 Deals
12.1.7 BIO-RAD LABORATORIES, INC.
12.1.7.1 Business overview
12.1.7.2 Products & services offered
12.1.7.3 Recent developments
12.1.7.3.1 Product launches
12.1.8 CORNING INCORPORATED
12.1.8.1 Business overview
12.1.8.2 Products & services offered
12.1.8.3 Recent developments
12.1.8.3.1 Product launches
12.1.9 METTLER-TOLEDO INTERNATIONAL INC.
12.1.9.1 Business overview
12.1.9.2 Products & services offered
12.1.9.3 Recent developments
12.1.9.3.1 Product launches
12.1.10 LONZA GROUP
12.1.10.1 Business overview
12.1.10.2 Products & services offered
12.1.10.3 Recent developments
12.1.10.3.1 Deals
12.1.11 WATERS CORPORATION
12.1.11.1 Business overview
12.1.11.2 Products & services offered
12.1.11.3 Recent developments
12.1.11.3.1 Product launches
12.1.11.3.2 Deals
12.1.12 SARTORIUS AG
12.1.12.1 Business overview
12.1.12.2 Products & services offered
12.1.12.3 Recent developments
12.1.12.3.1 Product launches
12.1.13 EPPENDORF SE
12.1.13.1 Business overview
12.1.13.2 Products & services offered
12.1.13.3 Recent developments
12.1.13.3.1 Deals
12.1.13.3.2 Expansions
12.1.14 PORVAIR PLC
12.1.14.1 Business overview
12.1.14.2 Products & services offered
12.1.15 GREINER AG
12.1.15.1 Business overview
12.1.15.2 Products & services offered
12.1.16 CHARLES RIVER LABORATORIES
12.1.16.1 Business overview
12.1.16.2 products & services offered
12.1.16.3 Recent developments
12.1.16.3.1 Deals
12.1.17 EUROFINS SCIENTIFIC
12.1.17.1 Business overview
12.1.17.2 Products & services offered
12.1.17.3 Recent developments
12.1.17.3.1 Service launches
12.1.17.3.2 Deals
12.1.17.3.3 Expansions
12.1.18 HAMILTON COMPANY
12.1.18.1 Business overview
12.1.18.2 Products & services offered
12.1.18.3 Recent developments
12.1.18.3.1 Product launches
12.1.18.3.2 Deals
12.1.19 AURORA BIOMED INC.
12.1.19.1 Business overview
12.1.19.2 Products & services offered
12.1.20 GILSON INCORPORATED
12.1.20.1 Business overview
12.1.20.2 Products & services offered
12.1.20.3 Recent developments
12.1.20.3.1 Product launches
12.1.20.3.2 Deals
12.1.21 BRAND GMBH + CO KG
12.1.21.1 Business overview
12.1.21.2 Products & services offered
12.1.21.3 Recent developments
12.1.21.3.1 Expansions
12.2 OTHER PLAYERS
12.2.1 BMG LABTECH GMBH
12.2.2 DIANA BIOTECHNOLOGIES, A.S.
12.2.3 CREATIVE BIOLABS
12.2.4 HIGHRES BIOSOLUTIONS
12.2.5 BIOMAT SRL
12.2.6 AXXAM S.P.A.
12.2.7 SYGNATURE DISCOVERY LIMITED
12.2.8 CROWN BIOSCIENCE
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
